Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05984277 · ClinicalTrials.gov registry record · Phase 3

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

A Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
1,200
Enrollment target
20
Study locations

NCT05984277 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,200 participants, above the 354-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (239% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05984277, a Phase 3 study of Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,200 participants
Enrollment target
20
Study locations

Study Summary

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.

Conditions Studied

Metastatic Non Small Cell Lung Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG Paclitaxel
  • DRUG Volrustomig

Study Locations (20)

Florida

  • Research Site - Fort Myers
  • Research Site - Gainesville
  • Research Site - Orlando
  • Research Site - St. Petersburg
  • Research Site - West Palm Beach

Maryland

  • Research Site - Annapolis
  • Research Site - Baltimore
  • Research Site - Silver Spring
  • Research Site - Towson

Arkansas

  • Research Site - Hot Springs
  • Research Site - Springdale

Indiana

  • Research Site - Fort Wayne
  • Research Site - Indianapolis

Kentucky

  • Research Site - Lexington
  • Research Site - Louisville

Arizona

  • Research Site - Prescott

California

  • Research Site - Long Beach

Colorado

  • Research Site - Lone Tree

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2023-10-24
Est. Completion 2029-03-23
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05984277

The ClinicalTrials.gov registry entry for NCT05984277 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 354-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (239% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT05984277 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Maryland, Arkansas.

Frequently Asked Questions

What is clinical trial NCT05984277 about?

NCT05984277 is a clinical study titled "A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.". The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.

What is the current status of trial NCT05984277?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2023-10-24. Estimated completion is 2029-03-23.

What conditions does trial NCT05984277 study?

This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.

What interventions are being tested in trial NCT05984277?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Volrustomig (DRUG).

Who is sponsoring clinical trial NCT05984277?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05984277 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Non Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Non Small Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.